SlideShare uma empresa Scribd logo
1 de 35
Baixar para ler offline
GDS_70000_Title_v1 1
HRT : An Update of Evidence
Hesham Al-Inany, M.D, PhD
Outline
• Menopausal transition
• HRT modalities
• Risks & Benefits
• Emerging concept
What is Menopausal transition?
• Menopause : permanent cessation of menstruation resulting from loss of
ovarian follicular activity (WHO, 2002)
• Menopausal transition: from the first features of approaching menopause until up
to 1 year after final menstrual period
• Associated with significant hormonal variability over time
• Overall, decline in estrogen levels over the menopausal transition
Burger HG et al. Hormonal changes in the menopause transition. J Clin Endocrinol Metab 2002;84:4025–30. Copyright 2002, The
Endocrine Society.
Years around menopause
Estradiol(pmol/L)
FSH(iu/L)
0 1 2 3 4 5-1-2-3-4
0
20
40
60
80
100
120
0
50
100
150
200
250
300
AMH & Menopausal transition (2014)
• prediction of age of menopause using AntiMullerian Hormone
• Both AMH and mother's ANM have added value in forecasting TTM
for the daughter based on her age (Dólleman M et al, 2014)
Signs and Symptoms
During the Menopausal Transition
Adapted from Bungay G et al. Br Med J 1980;281:181–3;
Van Keep PA et al. Maturitas 1990;12:163–70.
Vasomotor Symptoms
Sleep Disorders
Mood Changes Urogenital Atrophy
Dyspareunia
Osteoporosis
Atherosclerosis
Coronary Heart Disease
Cerebrovascular Disease
40 yrs 50 yrs
Menopause
60 yrs
Menstrual Disorders
Prevalence of Vasomotor Symptoms by Years
to/from the Final Menstrual Period (2008)
• Meta-analysis of six studies to estimate the natural progression of vasomotor
symptoms during the menopause transition : 4- 8 yrs
Figure reproduced with kind permission from Springer Science+Business Media: J Gen Intern Med,
Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. 23, 2008, 1507–13,
Politi MC, Schleinitz MD, Col NF, Figure 2.
Menopause
0
10
20
30
40
50
60
70
80
90
100
Percentagewithvasomotor
symptomsvv
Years to/from final menstrual period
Y-8 Y-7 Y-6 Y-5 Y-4 Y-3 Y-2 Y-1 Y0 Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 Y11 Y12 Y13 Y14 Y15 Y16
McKinlay (1974)
Gutherie (2003)
Thompson (1973)
Oldenhave (1993)
Berg (1988)
Nedstrand (1996)
• Penn Ovarian Aging Study 2007
• Data on 404 women who were
followed for a span of 9 years
– 50% White
– 50% African American
Prevalence and Severity of
Symptoms by Menopausal Stage
Freeman EW, Sammel MD, Lin H, Gracia CR, Pien GW, Nelson DB, Sheng L. Symptoms associated
with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol
2007;110:230–40.
73%
Subjects(%)
Aches
Subjects(%)
Decreased libido
Subjects(%)
Depression
80
60
40
20
0
Subjects(%)
Vaginal dryness
Subjects(%)
Hot flushes
Subjects(%)
Poor sleep
Menopausal stage Menopausal stage
Mild
Moderate or severe
80
60
40
20
0
80
60
40
20
0
80
60
40
20
0
80
60
40
20
0
80
60
40
20
0
Figure modified with permission from Obermeyer CM, Menopause Across Cultures: A Review of the Evidence, Menopause, 7, 3:184-92.
Comparative Frequencies of Hot Flushes in
Different Parts of the World
• A review of cross-cultural evidence on vasomotor symptoms from
available studies
HRT Remains the Most Effective Therapy for
Vasomotor Symptoms 2006
• No significant efficacy of botanicals in reducing vasomotor symptoms
Newton KM et al. Ann Intern Med 2006;145:869–79. Reprinted from Annals of Internal Medicine, 145, Newton et al, Treatment of
Vasomotor Symptoms of Menopause with Black Cohosh, Multibotanicals, Soy, Hormone Therapy, or Placebo, 869-879,
Copyright (2006), with permission from American College of Physicians.
Baseline 3 months 6 months 12 months
0
1
2
3
4
5
6
7
8
Vasomotorsymptomsperday
Black Cohosh
Multibotanical
Multibotanical + soy
HRT: CEE +/- MPA
Placebo
Outline
• Menopausal transition
• HRT modalities
• Risks & Benefits
• Emerging concept
Uterus
Sequential therapy without tablet break
Regular bleeding at end of cycle
How is HRT Given?
Continuous Sequential HRT
Estrogen
Progestogen
Day 14
De Villiers TJ et al. Climacteric 2013;16:316–337.
.
Continuous Estrogen
Estrogen
No tablet break
No bleeding as no uterus
Uterus
Continuous Combined HRT
Estrogen
Progestogen
Day 14 Combined therapy without tablet break
No bleeding at end of cycle
Estrogens Used in HRT 2007
Equivalent dose for bone endpoints*
Estrogen Ultra Low Low Standard High
Conjugated equine estrogens (mg) 0.151 0.3 0.625 1.25
Micronized 17β-estradiol (mg) 0.52 1 2 4
Estradiol valerate (mg) 1 2
Transdermal 17β-estradiol (μg) 143 25 50 100
*Estrogenic effects may vary for other endpoints
Table reproduced from Maturitas, 40, Gambacciani M, Genazzani AR. Hormone replacement therapy: the
benefits in tailoring the regimen and dose. 195–201, Copyright (2001), with permission from Elsevier.
1. Lindsay R et al. Obstet Gynecol 1984;63:759–63; 2. Panay N et al. Climacteric 2007;10:120–31;
The Estrogen Dose Counts
Estradiol: Benefits on Vasomotor Symptoms
• Dose–response effect for reducing moderate-to-severe hot flushes (n=333)
Figure reproduced with permission from Notelovitz M, Lenihan JP, Mcdermott M, Kerber IJ, Nanavati N,
Arce JC. Initial 17β-Estradiol Dose for Treating Vasomotor Symptoms. Obstet Gynecol 2000;95:726–31.
*p<0.05, ***p<0.001 vs. placebo
*
*
Meannumberofmoderate-to-
severehotflushesperweek
Weeks
0
10
20
30
40
50
60
70
80
0 1 2 3 4 5 6 7 8 9 10 11 12
Placebo
0.25 mg Estradiol
0.5 mg Estradiol
1 mg Estradiol
2 mg Estradiol
***
***
***
*
*
*
Role of Progestogens in HRT
• Estrogen provides the benefits of HRT on menopausal symptoms
• For women who have not had a hysterectomy, the addition of a progestogen to HRT is necessary
to protect the endometrium from the stimulatory effects of unopposed estrogen
Writing Group for the PEPI Trial. JAMA 1996;275:370–5.
PEPI Trial: multicenter RCT : Results of Endometrial Biopsy
Conclusion: Adding a progestogen is needed to safeguard the endometrium
Placebo CEE alone CEE+MPA
sequential
CEE+MPA
continuous
N 119 119 118 120
Normal 98% 38% 95% 99%
Simple hyperplasia 1% 28% 3% 1%
Complex hyperplasia 1% 23% 2% 0%
Atypia 0% 12% 0% 0%
Adenocarcinoma 1% 0% 0% 0%
Progestogens: Receptor Binding Activity
Progestogen Progestogenic Estrogenic Androgenic
Anti-
androgenic
Glucocorticoid
Anti-mineralo-
corticoid
Progesterone + – – ± + +
Dydrogesterone + – – ± – ±
Drospirenone + – – + – +
MPA + – ± – + –
Norethisterone + + + – – –
Table reproduced from Maturitas, 46 (S1), Schindler AE, Campagnoli C, Druckman R, Huber J,
Pasqualini JR, Schweppe KW, Thijssen JHH. Classification and pharmacology of progestins. 7–16.
Copyright (2003),
The Progestogen Counts
• All progestogens have a protective effect on the endometrium
• However, not all progestogens have the same receptor binding effect
+ Effective; ± Weakly effective; – Not effective
2013 IMS Recommendations on Menopausal
Hormone Therapy – General Principles for Use
• HRT remains the most effective therapy for vasomotor symptoms
• Use lowest effective dose of estrogen
• More favorable if treatment is started earlier in menopause
De Villiers TJ et al. Climacteric 2013;16:316–337.
.
Outline
• Menopausal transition
• HRT modalities
• Risks & Benefits
• Emerging concept
HRT Risks and Benefits
Benefits
Relief of
Menopause
Symptoms
Risks
Breast
Cancer
Odds ratio (fixed)
95% CI
1.00 [0.68, 1.46]
1.02 [0.06, 16.44]
0.92 [0.41, 2.07]
0.98 [0.78, 1.22]
0.50 [0.04, 5.54]
0.32 [0.01, 8.24]
0.97 [0.06, 15.82]
2.64 [0.10, 66.41]
0.33 [0.01, 8.21]
0.97 [0.54, 1.72]
1.79 [0.42, 7.67]
1.26 [0.96, 1.64]
0.97 [0.78, 1.21]
Total 1.03 [0.91, 1.16]
HRT Reduced the Risk of CHD events in
Younger Postmenopausal Women (2006)In a meta-analysis of data from 23 studies (n=39,049)
• HRT reduced CHD events by 32% in younger* women
• In older women**, there was no reduction in CHD with HRT (OR 1.03; CI 0.91 to 1.16)
*<10 years post-menopause or <60 years; **≥10 years post-menopause or ≥60 years
CHD, coronary heart disease; OR, odds ratio
Odds ratio (fixed)
95% CI
3.03 [0.12, 75.28]
0.16 [0.01, 4.12]
3.03 [0.12, 75.06]
1.00 [0.06, 16.10]
0.33 [0.01, 3.19]
1.25 [0.06, 26.10]
0.33 [0.01, 8.12]
0.31 [0.01, 8.29]
0.05 [0.00, 1.16]
0.12 [0.00, 2.93]
0.87 [0.53, 1.41]
0.56 [0.30, 1.03]
Total 0.68 [0.48, 0.96]
0.001
Favors HT Favors control Favors HT
0.01 0.1 1 10 100
Favors control
Older women**
1000.01 0.1 1 10
Younger women*
Figure reproduced with kind permission from Springer Science+Business Media: J Gen Intern Med, Coronary
Heart Disease Events Associated with Hormone Therapy in Younger and Older Women, 21, 2006, 363-66,
Salpeter SR, Walsh JME, Greyber E, Salpeter EE, Figures 1 & 2.
HRT and the Risk of Ischemic Stroke (WHI)
Risk of Ischemic Stroke
• The use of estrogen-only and estrogen-progestogen therapy is associated with an up to
1.5-fold increased relative risk of ischemic stroke. The risk of hemorrhagic stroke is not
increased during use of HRT. This relative risk is not dependent on age or on duration of
use, but as the baseline risk is strongly age-dependent, the overall risk of stroke in women
who use HRT will increase with age
US WHI studies combined - additional risk of ischemic stroke1 over 5 years’ use
Age range
(years)
Incidence per 1,000 women
in placebo arm over 5 years
Risk ratio
(95% CI)
Additional cases per 1,000
HRT users over 5 years (95% CI)
50–59 8 1.3 (1.1–1.6) 3 (1–5)
1No differentiation was made between ischemic and hemorrhagic stroke
Risk of Stroke Associated with Route of
Administration (2010)
• Case-control study from the UK General Practice Research Database
Renoux C et al. BMJ 2010;340:c2519.
• Low-dose transdermal HRT did not appear to increase stroke risk
(1.15–
3.11)
(0.62–
1.05)
(1.12–
1.40)
(1.16–
1.90)
AdjustedRRvs.never-use
ofHRT(95%CI)
Risk of Thromboembolism Associated with
Different Progestogens (2007)
ESTHER case-control study
271 consecutive VTE cases (mean age: 61.6 years) and 610 controls (mean age: 61.5 years)
Canonico M. Circulation 2007;115:840–5.
AdjustedORs(95%CI)for
VTEwithoralandtransdermal
estrogenvs.non-users
(e.g. Dydrogesterone)
 Micronized progesterone and dydroprogesterone
appear to have an acceptable thrombotic risk profile
4.2 (1.5–11.6)
0.7 (0.3–1.9) 0.9 (0.4–2.3)
3.9 (1.5–10.0)
(e.g. Nomegestrol acetate)
Breast Cancer with HRT: Risk Perception vs. Reality
Figure reproduced with permission from http://www.keepstudy.org/why_keeps/keeps_causeDeath.pdf. Accessed
1 November 2012
PERCEPTION
Leading causes of death
perceived by women
REALITY
Actual causes of death
among US women
Old age (1%)
Heart
disease
(18%)
Other
cancer
(13%)
Breast cancer
(39%)
Lung
cancer
(2%)
Ovarian
cancer (9%)
Stress (2%)
Smoking (1%)
Other/don’t
know (16%)
Heart
disease
(45%)
Other (25%)
Lung
cancer
(5%)
Ovarian cancer (<2%)
COPD (4%)
Pneumonia (4%)
Other
cancer
(11%)
Breast cancer (4%)
Growth
1 cm
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Years
2.5 cm1 mm
Pre-mammographic Mammographic
Window
Clinically detected
Breast
Tumor
Chronological Development of Breast Cancer
2011
Fritz MA and Speroff L. Clinical Gynecologic Endocrinology and Infertility (8th edn) Wolters Kluwer 2011; pp. 667–8.
Is HRT Associated with Increased Breast Cancer Risk?
Evidence from WHI
1. Rossouw JE et al. JAMA 2002;288:321–33; 2. Langer R et al. Climacteric 2012;15:206–12; 3.
Stefanik M et al. JAMA 2006;295:1647–57; 4. Santen R et al. J Clin Endocrinol Metab
2010;95(Suppl 1):s1–66; 5. Gompel A et al. Climacteric 2012;15:241–9.
WHI
evidence
WHI RR for breast cancer:
1.26 (95% CI 1.00–1.59)
for current use of HRT
(CEE + MPA)1
Relative risk of 1.26 with combined HRT
translates to an excess (attributable) risk of
4 per 1000 women taking HRT for 5 years4
Excess risk of breast cancer
from HRT increases with
increase in underlying risk5
Determination of risk should
underlie decision to use HRT
• No increased risk was
identified for women who had
had hysterectomy receiving
CEE alone 2012
HRT and Breast Cancer Risk - WHI
US WHI studies – additional risk of breast cancer after 5 years’ use
Age range
(years)
Incidence per 1,000 women
in placebo arm over 5 years
Risk ratio
(95% CI)
Additional cases per 1,000
HRT users over 5 years (95% CI)
CEE estrogen-only
50–79 21 0.8 (0.7–1.0) -4 (-6–0)1
CEE + MPA
50–79 14 1.2 (1.0–1.5) +4 (0–9)
When the analysis was restricted to women who had not used HRT prior to the study there was no
increased risk apparent during the first 5 years of treatment: after 5 years the risk was higher than
non-users
1 WHI study in women with no uterus, which did not show an increase in risk of breast cancer
Netherlands Summary of Product Characteristics (SmPC) , estradiol/dydrogesterone 2/10, 1/10, 1/5, 0.5/2.5 issued 13 April 2012.
HRT and Breast Cancer Risk – Million Women Study
Million Women Study – Estimated additional risk of breast cancer after 5 years’ use
Age range
(years)
Additional cases per 1,000 never
users of HRT over a 5 year
period1
Risk ratio
(95% CI) #
Additional cases per 1,000
HRT users over 5 years (95% CI)
Estrogen only HRT
50–65 9–12 1.2 1–2 (0–3)
Combined estrogen-progestogen
50–65 9–12 1.7 6 (5–7)
# Overall risk ratio. The risk ratio is not constant but will increase with increasing duration of use
Note: Since the background incidence of breast cancer differs by EU country, the number of additional
cases of breast cancer will also change proportionately
1Taken from baseline incidence rates in developed countries
Netherlands Summary of Product Characteristics (SmPC) , estradiol/dydrogesterone 2/10, 1/10, 1/5, 0.5/2.5 issued 13 April 2012.
Choice of Progestogen and Breast Cancer Risk:
E3N French Cohort Study 2008
Fournier A et al. Breast Cancer Res Treat 2008;107:103–11;
Fournier A et al. J Clin Oncol. 2008 ;26:1260–1268.
Risk of all breast cancer
Risk elevation may not be uniform for all progestogens
N = 80,377 women, for an average treatment duration of 8.1 years
Overall 77.7% were ductal breast cancers vs. 22.3% lobular breast cancers
Estrogen/other
progestogens
(0.83–
1.22)
(0.94–
1.43)
(1.50–
1.91)
1.16
1.00
Estrogen/
progesterone
Baseline risk
without HRT
Estrogen/
dydrogesterone
1.69
0
0.2
0.4
0.8
1.2
1.6
1.0
2.2
2.0
1.8
1.4
0.6
Relativerisk(95%CI)
≥5 years
(0.8–
1.5)
(0.8–
2.7)
(1.2–
3.8)
1.5
1.1
≥5 years<5 years <5 years
2.1
0
0.2
0.4
0.8
1.2
1.6
1.0
2.2
2.0
1.8
1.4
0.6
Ductal carcinoma Lobular carcinoma
1.1
(0.8–
1.17)
Risk of breast cancer subtypes with
E/D
Significantly different from the risk without HRT
Not statistically significantly different from risk without HRT
Choice of Progestogen and Breast Cancer Risk:
Finnish Cohort Study 2009
Lyytinen H et al. Obst Gyn 2009;113:65–73.
Estradiol/
MPA
Estradiol/other
progestogens
Standardincidenceratio(95%CI)
0
0.2
0.4
0.8
1.2
1.6
1.0
2.2
2.0
1.8
1.4
0.6
2.072.03
1.64
1.13
Estradiol/
dydrogesterone
Estradiol/
NETA
(0.49–
2.22)
(1.49–
1.79)
(1.88–
2.18)
(1.76–
2.04)
Baseline risk
without HRT
Risk elevation may not be uniform for all progestogensRisk elevation may not be uniform for all progestogens
N = 50,210 women >50 years of age, treatment duration 5 years
Statements from International Societies 2013
International Menopause Society Statement on Breast Cancer1
• Women should be reassured that the possible increased risks of breast cancer
associated with HRT are small
• an incidence of <1.0 per 1000 women per year of use
• Less than the increased risks associated with common lifestyle factors such as reduced physical activity,
obesity and alcohol consumption
• Micronized progesterone or dydrogesterone used with estradiol may be associated with a better
risk profile for breast cancer than synthetic progestogens
1. De Villiers TJ et al. Climacteric 2013;16:316–337.
2. Santen R et al. J Clin Endocrinol Metab 2010;95(Suppl1):S1–S66.
USA Endocrine Society Scientific Statement on Breast Cancer2
• Emerging data from 2 independent studies suggest that progesterone (and perhaps
dydrogesterone) in combination with estrogen does not increase breast cancer risk if
given for 5 years or less
Outline
• Menopausal transition
• HRT modalities
• Risks & Benefits
• Emerging concept
Sequential Estradiol/Dydrogesterone:
Endometrial Safety and Bleeding
• In a comparison of 1/5 or 1/10 vs. 2/10 or 2/20 (n=579)1
– Endometrial safety was recorded across groups
• No cases of hyperplasia or malignancy with 1/10 and 2/10
• 1 polyp occurred with 1/10
– Cyclic bleeding patterns were seen
• Percentage of women with cyclic bleeding was 79% with 1/10 and
91% with 2/10
• E 1 mg associated with less cyclic and intermittent bleeding vs. E 2 mg
• Higher doses of D associated with higher incidence of bleeds and later day
of onset
• In a comparison of 2/5, 2/10, 2/15 or 2/20 (n=371):2
– Endometrial safety was recorded across groups
• No cases of hyperplasia or malignancy with 1/10 and 2/10
– Cyclic bleeding patterns found at all doses (83%, 90%, 87%, 93%, respectively)
• Percentage of women with cyclic bleeding was 90% with 2/10
1. Ferenczy A et al. Climacteric 2002;5:26–35;
2. Burch DJ et al. Brit J Obst Gynaecol 1995;102:243–8.
Continuous Estradiol/Dydrogesterone:
Endometrial Safety and Bleeding Patterns 2010
• In an open, multicenter study of 1/5 for 1 year (n=290):1
• 1 case of simple hyperplasia without atypia (treatment failure rate of 0.4%)
• Women without bleeding increased from 71% (cycle 1) to ~80% by end of the study
• ~50% of bleeding episodes were spotting
• 41% women were amenorrheic throughout the study
• 7 women withdrew prematurely due to uterine bleeding
• In an open, multicenter study of ultra-low-dose 0.5/2.5 over 1 year (n=446):2
• 1 case of simple hyperplasia (incidence: 0.27%)
• 68% experienced amenorrhea (88% during months 10–12)
• 14% had 1 or 2 bleeding/spotting episodes
• Spotting alone was the most prevalent bleeding intensity; heavy bleeding was rare
1. Quereux C et al. Maturitas 2006;53:299–305;
2. Bergeron C et al. Maturitas 2010;66:201–5.
The emerging concepts in HRT
• Timing (window of opportunity)
• Early start
• Maintenance of estrogenic benefits
• Patient selection
• Avoiding generalized prescribing
• Personalization
• Tailoring dose to patient
• Continuation and tapering the dose with age
Conclusion
Used by the right woman, at the right dose, HRT can:
• Relieve vasomotor and other menopausal symptoms
• Provide protection against bone loss (second line)
• Provide acceptable bleeding patterns

Mais conteúdo relacionado

Mais procurados

Understanding Menopause
Understanding Menopause Understanding Menopause
Understanding Menopause schhasatia
 
Case Based Panel Discussion on Menopausal health
Case Based Panel Discussion on Menopausal healthCase Based Panel Discussion on Menopausal health
Case Based Panel Discussion on Menopausal healthSujoy Dasgupta
 
Menopause: When to use HRT?
Menopause: When to use HRT?Menopause: When to use HRT?
Menopause: When to use HRT?Galal Lotfi
 
Recurrent pregnancy loss: case scenario
Recurrent pregnancy loss: case scenarioRecurrent pregnancy loss: case scenario
Recurrent pregnancy loss: case scenarioAboubakr Elnashar
 
GnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian StimulationGnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian StimulationSandro Esteves
 
Palm coein classification its clinical significance -final
Palm coein classification  its  clinical significance -finalPalm coein classification  its  clinical significance -final
Palm coein classification its clinical significance -finalMAMTA RATH DATTA
 
Abnormal Uterine Bleeding (AUB).pptx
Abnormal Uterine Bleeding (AUB).pptxAbnormal Uterine Bleeding (AUB).pptx
Abnormal Uterine Bleeding (AUB).pptxabdelrhman90
 
HORMONE REPLACEMENT THERAPY
HORMONE REPLACEMENT THERAPY HORMONE REPLACEMENT THERAPY
HORMONE REPLACEMENT THERAPY Karl Daniel, M.D.
 
Step by Step Guide to Menopause Hormone Therapy by Dr. laxmi Shrikhande
Step by Step Guide to Menopause Hormone Therapy by Dr. laxmi ShrikhandeStep by Step Guide to Menopause Hormone Therapy by Dr. laxmi Shrikhande
Step by Step Guide to Menopause Hormone Therapy by Dr. laxmi ShrikhandeDr.Laxmi Agrawal Shrikhande
 
Endometrial carcinoma.lecture by Associate Professor Dr Aisha Elbareg
Endometrial carcinoma.lecture by Associate Professor Dr Aisha ElbaregEndometrial carcinoma.lecture by Associate Professor Dr Aisha Elbareg
Endometrial carcinoma.lecture by Associate Professor Dr Aisha ElbaregDr. Aisha M Elbareg
 
Fertility preservation in Cancer Cervix
Fertility preservation in Cancer CervixFertility preservation in Cancer Cervix
Fertility preservation in Cancer CervixSujoy Dasgupta
 

Mais procurados (20)

Understanding Menopause
Understanding Menopause Understanding Menopause
Understanding Menopause
 
Non-contraceptive Benefits of COCP
Non-contraceptive Benefits of COCPNon-contraceptive Benefits of COCP
Non-contraceptive Benefits of COCP
 
Case Based Panel Discussion on Menopausal health
Case Based Panel Discussion on Menopausal healthCase Based Panel Discussion on Menopausal health
Case Based Panel Discussion on Menopausal health
 
Menopause: When to use HRT?
Menopause: When to use HRT?Menopause: When to use HRT?
Menopause: When to use HRT?
 
Menopause
MenopauseMenopause
Menopause
 
Menopause by Dr Shahjada Selim
Menopause by Dr Shahjada SelimMenopause by Dr Shahjada Selim
Menopause by Dr Shahjada Selim
 
menopause and hormone replacement therapy hrt (1)
menopause and hormone replacement therapy hrt  (1)menopause and hormone replacement therapy hrt  (1)
menopause and hormone replacement therapy hrt (1)
 
Hrt
HrtHrt
Hrt
 
Recurrent pregnancy loss: case scenario
Recurrent pregnancy loss: case scenarioRecurrent pregnancy loss: case scenario
Recurrent pregnancy loss: case scenario
 
GnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian StimulationGnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian Stimulation
 
Menopause
MenopauseMenopause
Menopause
 
Palm coein classification its clinical significance -final
Palm coein classification  its  clinical significance -finalPalm coein classification  its  clinical significance -final
Palm coein classification its clinical significance -final
 
Menopause & HRT
Menopause & HRTMenopause & HRT
Menopause & HRT
 
Abnormal Uterine Bleeding (AUB).pptx
Abnormal Uterine Bleeding (AUB).pptxAbnormal Uterine Bleeding (AUB).pptx
Abnormal Uterine Bleeding (AUB).pptx
 
HORMONE REPLACEMENT THERAPY
HORMONE REPLACEMENT THERAPY HORMONE REPLACEMENT THERAPY
HORMONE REPLACEMENT THERAPY
 
Step by Step Guide to Menopause Hormone Therapy by Dr. laxmi Shrikhande
Step by Step Guide to Menopause Hormone Therapy by Dr. laxmi ShrikhandeStep by Step Guide to Menopause Hormone Therapy by Dr. laxmi Shrikhande
Step by Step Guide to Menopause Hormone Therapy by Dr. laxmi Shrikhande
 
Menopause
MenopauseMenopause
Menopause
 
Endometrial carcinoma.lecture by Associate Professor Dr Aisha Elbareg
Endometrial carcinoma.lecture by Associate Professor Dr Aisha ElbaregEndometrial carcinoma.lecture by Associate Professor Dr Aisha Elbareg
Endometrial carcinoma.lecture by Associate Professor Dr Aisha Elbareg
 
Menopause
MenopauseMenopause
Menopause
 
Fertility preservation in Cancer Cervix
Fertility preservation in Cancer CervixFertility preservation in Cancer Cervix
Fertility preservation in Cancer Cervix
 

Destaque

Evidence based diagnosis
Evidence based diagnosisEvidence based diagnosis
Evidence based diagnosisHesham Al-Inany
 
Elagolix for endometriosis
Elagolix for endometriosisElagolix for endometriosis
Elagolix for endometriosisHesham Al-Inany
 
Twins after IVF : revisited
Twins after IVF : revisitedTwins after IVF : revisited
Twins after IVF : revisitedHesham Al-Inany
 
Investigation of infertility modified
Investigation of infertility modifiedInvestigation of infertility modified
Investigation of infertility modifiedHesham Al-Inany
 
Management of endometrial hyperplasia
Management of endometrial hyperplasiaManagement of endometrial hyperplasia
Management of endometrial hyperplasiaAhmad Saber
 
Wiki.placental abnormalities1
Wiki.placental abnormalities1Wiki.placental abnormalities1
Wiki.placental abnormalities1cslonern
 
Current Management of Anovulatory Infertility
Current Management of Anovulatory InfertilityCurrent Management of Anovulatory Infertility
Current Management of Anovulatory InfertilityWale Jesudemi
 
How to establish an ivf center
How to establish an ivf centerHow to establish an ivf center
How to establish an ivf centerHesham Al-Inany
 
laparoscopic radical hysterectomy for carcinoma cervix Female Pelvic Anatomy ...
laparoscopic radical hysterectomy for carcinoma cervix Female Pelvic Anatomy ...laparoscopic radical hysterectomy for carcinoma cervix Female Pelvic Anatomy ...
laparoscopic radical hysterectomy for carcinoma cervix Female Pelvic Anatomy ...Pradeep Garg
 
Designing a good ivf service
Designing a good ivf serviceDesigning a good ivf service
Designing a good ivf serviceSawad thotathil
 
Ovarian stimulation oral agents
Ovarian stimulation oral agentsOvarian stimulation oral agents
Ovarian stimulation oral agentsAhmad Saber
 
How to Setup IUI and IVF Services
How to Setup IUI and IVF ServicesHow to Setup IUI and IVF Services
How to Setup IUI and IVF ServicesPriya Bhave.
 
Imaging of the placenta
Imaging of the placentaImaging of the placenta
Imaging of the placentathambimbbs
 
Endometrial hyperplasia
Endometrial hyperplasiaEndometrial hyperplasia
Endometrial hyperplasiaOsama Warda
 
Ovulation induction protocols in ivf cycles. warda
Ovulation induction protocols in ivf cycles. wardaOvulation induction protocols in ivf cycles. warda
Ovulation induction protocols in ivf cycles. wardaOsama Warda
 

Destaque (20)

CF twin preg 11-3-16
CF twin preg 11-3-16CF twin preg 11-3-16
CF twin preg 11-3-16
 
Evidence based diagnosis
Evidence based diagnosisEvidence based diagnosis
Evidence based diagnosis
 
Selective progesterone
Selective progesteroneSelective progesterone
Selective progesterone
 
Elagolix for endometriosis
Elagolix for endometriosisElagolix for endometriosis
Elagolix for endometriosis
 
Twins after IVF : revisited
Twins after IVF : revisitedTwins after IVF : revisited
Twins after IVF : revisited
 
Investigation of infertility modified
Investigation of infertility modifiedInvestigation of infertility modified
Investigation of infertility modified
 
Doppler in diagnosis of placental invasion
Doppler in diagnosis of placental invasionDoppler in diagnosis of placental invasion
Doppler in diagnosis of placental invasion
 
Management of endometrial hyperplasia
Management of endometrial hyperplasiaManagement of endometrial hyperplasia
Management of endometrial hyperplasia
 
Wiki.placental abnormalities1
Wiki.placental abnormalities1Wiki.placental abnormalities1
Wiki.placental abnormalities1
 
Current Management of Anovulatory Infertility
Current Management of Anovulatory InfertilityCurrent Management of Anovulatory Infertility
Current Management of Anovulatory Infertility
 
How to establish an ivf center
How to establish an ivf centerHow to establish an ivf center
How to establish an ivf center
 
Multiple pregnancy
Multiple pregnancyMultiple pregnancy
Multiple pregnancy
 
laparoscopic radical hysterectomy for carcinoma cervix Female Pelvic Anatomy ...
laparoscopic radical hysterectomy for carcinoma cervix Female Pelvic Anatomy ...laparoscopic radical hysterectomy for carcinoma cervix Female Pelvic Anatomy ...
laparoscopic radical hysterectomy for carcinoma cervix Female Pelvic Anatomy ...
 
Designing a good ivf service
Designing a good ivf serviceDesigning a good ivf service
Designing a good ivf service
 
Ovarian stimulation oral agents
Ovarian stimulation oral agentsOvarian stimulation oral agents
Ovarian stimulation oral agents
 
Laparoscopy 4
Laparoscopy  4Laparoscopy  4
Laparoscopy 4
 
How to Setup IUI and IVF Services
How to Setup IUI and IVF ServicesHow to Setup IUI and IVF Services
How to Setup IUI and IVF Services
 
Imaging of the placenta
Imaging of the placentaImaging of the placenta
Imaging of the placenta
 
Endometrial hyperplasia
Endometrial hyperplasiaEndometrial hyperplasia
Endometrial hyperplasia
 
Ovulation induction protocols in ivf cycles. warda
Ovulation induction protocols in ivf cycles. wardaOvulation induction protocols in ivf cycles. warda
Ovulation induction protocols in ivf cycles. warda
 

Semelhante a 2014 :Updated information on Hormone Replacement Therapy

Updated hormone replacement therapy
Updated hormone replacement therapyUpdated hormone replacement therapy
Updated hormone replacement therapyHesham Al-Inany
 
Q and A's - Breast Cancer Survivors and Menopausal symptoms- Hormonal and non...
Q and A's - Breast Cancer Survivors and Menopausal symptoms- Hormonal and non...Q and A's - Breast Cancer Survivors and Menopausal symptoms- Hormonal and non...
Q and A's - Breast Cancer Survivors and Menopausal symptoms- Hormonal and non...Marmara University School of Medicine
 
Hormone Replacement Therapy and Breast Cancer
Hormone Replacement Therapy and Breast CancerHormone Replacement Therapy and Breast Cancer
Hormone Replacement Therapy and Breast CancerKervindran Mohanasundaram
 
Endocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast CancerEndocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast Cancerguest8887a7
 
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...Cleveland HeartLab, Inc.
 
EndometriosisUpdate.pptx
EndometriosisUpdate.pptxEndometriosisUpdate.pptx
EndometriosisUpdate.pptxHesham Al-Inany
 
Am 11.20 alexander
Am 11.20 alexanderAm 11.20 alexander
Am 11.20 alexanderplmiami
 
Senturk, lm emas webinar infertility and hyperandrogenism_20181205
Senturk, lm emas webinar infertility and hyperandrogenism_20181205Senturk, lm emas webinar infertility and hyperandrogenism_20181205
Senturk, lm emas webinar infertility and hyperandrogenism_20181205TrkiyeMenopozVeOsteo
 
Life after menopause
Life after menopauseLife after menopause
Life after menopauseEddie Lim
 
Case Study Number Two          In this weeks discussion.docx
Case Study Number Two          In this weeks discussion.docxCase Study Number Two          In this weeks discussion.docx
Case Study Number Two          In this weeks discussion.docxdrennanmicah
 
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...European School of Oncology
 
Testosterone e cancro alla prostata
Testosterone e cancro alla prostataTestosterone e cancro alla prostata
Testosterone e cancro alla prostataAdmin Esanum IT
 
Hormone replacement therapy
Hormone replacement therapy Hormone replacement therapy
Hormone replacement therapy Adeniji Adekoga
 
Adjuvant endocrine therapy in breast cancer
Adjuvant endocrine therapy in breast cancer   Adjuvant endocrine therapy in breast cancer
Adjuvant endocrine therapy in breast cancer Mamdouh Sabry
 

Semelhante a 2014 :Updated information on Hormone Replacement Therapy (20)

Updated hormone replacement therapy
Updated hormone replacement therapyUpdated hormone replacement therapy
Updated hormone replacement therapy
 
Updated HRT.pptx
Updated HRT.pptxUpdated HRT.pptx
Updated HRT.pptx
 
Q and A's - Breast Cancer Survivors and Menopausal symptoms- Hormonal and non...
Q and A's - Breast Cancer Survivors and Menopausal symptoms- Hormonal and non...Q and A's - Breast Cancer Survivors and Menopausal symptoms- Hormonal and non...
Q and A's - Breast Cancer Survivors and Menopausal symptoms- Hormonal and non...
 
Hormone Replacement Therapy and Breast Cancer
Hormone Replacement Therapy and Breast CancerHormone Replacement Therapy and Breast Cancer
Hormone Replacement Therapy and Breast Cancer
 
Endocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast CancerEndocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast Cancer
 
Dienogest in endometriosis
Dienogest in endometriosisDienogest in endometriosis
Dienogest in endometriosis
 
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
Holly Thacker, Update on: Menopause, Hormone Therapy, Sex, Politics, and the ...
 
EndometriosisUpdate.pptx
EndometriosisUpdate.pptxEndometriosisUpdate.pptx
EndometriosisUpdate.pptx
 
Am 11.20 alexander
Am 11.20 alexanderAm 11.20 alexander
Am 11.20 alexander
 
Senturk, lm emas webinar infertility and hyperandrogenism_20181205
Senturk, lm emas webinar infertility and hyperandrogenism_20181205Senturk, lm emas webinar infertility and hyperandrogenism_20181205
Senturk, lm emas webinar infertility and hyperandrogenism_20181205
 
Menopausal Hormone Replacement Therapy by Dr Shahjada Selim
Menopausal Hormone Replacement Therapy by Dr Shahjada SelimMenopausal Hormone Replacement Therapy by Dr Shahjada Selim
Menopausal Hormone Replacement Therapy by Dr Shahjada Selim
 
ET in MBC.pptx
ET in MBC.pptxET in MBC.pptx
ET in MBC.pptx
 
Life after menopause
Life after menopauseLife after menopause
Life after menopause
 
Case Study Number Two          In this weeks discussion.docx
Case Study Number Two          In this weeks discussion.docxCase Study Number Two          In this weeks discussion.docx
Case Study Number Two          In this weeks discussion.docx
 
Hormone replacement therapy
Hormone replacement therapyHormone replacement therapy
Hormone replacement therapy
 
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
BALKAN MCO 2011 - T. Cufer - Hormonal therapy options/management in metastati...
 
Testosterone e cancro alla prostata
Testosterone e cancro alla prostataTestosterone e cancro alla prostata
Testosterone e cancro alla prostata
 
Treatment of hot flushes
Treatment of hot flushesTreatment of hot flushes
Treatment of hot flushes
 
Hormone replacement therapy
Hormone replacement therapy Hormone replacement therapy
Hormone replacement therapy
 
Adjuvant endocrine therapy in breast cancer
Adjuvant endocrine therapy in breast cancer   Adjuvant endocrine therapy in breast cancer
Adjuvant endocrine therapy in breast cancer
 

Mais de Hesham Al-Inany

Mais de Hesham Al-Inany (20)

errors.pptx
errors.pptxerrors.pptx
errors.pptx
 
DienogestMEFS.pptx
DienogestMEFS.pptxDienogestMEFS.pptx
DienogestMEFS.pptx
 
4G O.I.pptx
4G O.I.pptx4G O.I.pptx
4G O.I.pptx
 
miscarriage.pptx
miscarriage.pptxmiscarriage.pptx
miscarriage.pptx
 
OBGYNTech.pptx
OBGYNTech.pptxOBGYNTech.pptx
OBGYNTech.pptx
 
progesterone & Miscarriage.pptx
progesterone & Miscarriage.pptxprogesterone & Miscarriage.pptx
progesterone & Miscarriage.pptx
 
How to use technology to improve data integrity.pptx
How to use technology to improve data integrity.pptxHow to use technology to improve data integrity.pptx
How to use technology to improve data integrity.pptx
 
Day 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transferDay 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transfer
 
Fibroid & infertility
Fibroid & infertilityFibroid & infertility
Fibroid & infertility
 
Prima IVF poor responders
Prima IVF  poor respondersPrima IVF  poor responders
Prima IVF poor responders
 
Adenomyosis
AdenomyosisAdenomyosis
Adenomyosis
 
Ohss
OhssOhss
Ohss
 
Future of IVF : scoping view
Future of IVF : scoping viewFuture of IVF : scoping view
Future of IVF : scoping view
 
Ethics &amp; infertility
Ethics &amp; infertilityEthics &amp; infertility
Ethics &amp; infertility
 
Updates in endometrial receptivity
Updates in endometrial receptivityUpdates in endometrial receptivity
Updates in endometrial receptivity
 
Prp & reproduction
Prp & reproductionPrp & reproduction
Prp & reproduction
 
Pitfalls in management of infertility
Pitfalls in management of infertilityPitfalls in management of infertility
Pitfalls in management of infertility
 
Ocp 24
Ocp 24Ocp 24
Ocp 24
 
Errors in IVF
Errors in IVFErrors in IVF
Errors in IVF
 
4G ovarian stimulation
4G ovarian stimulation 4G ovarian stimulation
4G ovarian stimulation
 

Último

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 

Último (20)

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 

2014 :Updated information on Hormone Replacement Therapy

  • 1. GDS_70000_Title_v1 1 HRT : An Update of Evidence Hesham Al-Inany, M.D, PhD
  • 2. Outline • Menopausal transition • HRT modalities • Risks & Benefits • Emerging concept
  • 3. What is Menopausal transition? • Menopause : permanent cessation of menstruation resulting from loss of ovarian follicular activity (WHO, 2002) • Menopausal transition: from the first features of approaching menopause until up to 1 year after final menstrual period • Associated with significant hormonal variability over time • Overall, decline in estrogen levels over the menopausal transition Burger HG et al. Hormonal changes in the menopause transition. J Clin Endocrinol Metab 2002;84:4025–30. Copyright 2002, The Endocrine Society. Years around menopause Estradiol(pmol/L) FSH(iu/L) 0 1 2 3 4 5-1-2-3-4 0 20 40 60 80 100 120 0 50 100 150 200 250 300
  • 4. AMH & Menopausal transition (2014) • prediction of age of menopause using AntiMullerian Hormone • Both AMH and mother's ANM have added value in forecasting TTM for the daughter based on her age (Dólleman M et al, 2014)
  • 5. Signs and Symptoms During the Menopausal Transition Adapted from Bungay G et al. Br Med J 1980;281:181–3; Van Keep PA et al. Maturitas 1990;12:163–70. Vasomotor Symptoms Sleep Disorders Mood Changes Urogenital Atrophy Dyspareunia Osteoporosis Atherosclerosis Coronary Heart Disease Cerebrovascular Disease 40 yrs 50 yrs Menopause 60 yrs Menstrual Disorders
  • 6. Prevalence of Vasomotor Symptoms by Years to/from the Final Menstrual Period (2008) • Meta-analysis of six studies to estimate the natural progression of vasomotor symptoms during the menopause transition : 4- 8 yrs Figure reproduced with kind permission from Springer Science+Business Media: J Gen Intern Med, Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. 23, 2008, 1507–13, Politi MC, Schleinitz MD, Col NF, Figure 2. Menopause 0 10 20 30 40 50 60 70 80 90 100 Percentagewithvasomotor symptomsvv Years to/from final menstrual period Y-8 Y-7 Y-6 Y-5 Y-4 Y-3 Y-2 Y-1 Y0 Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 Y11 Y12 Y13 Y14 Y15 Y16 McKinlay (1974) Gutherie (2003) Thompson (1973) Oldenhave (1993) Berg (1988) Nedstrand (1996)
  • 7. • Penn Ovarian Aging Study 2007 • Data on 404 women who were followed for a span of 9 years – 50% White – 50% African American Prevalence and Severity of Symptoms by Menopausal Stage Freeman EW, Sammel MD, Lin H, Gracia CR, Pien GW, Nelson DB, Sheng L. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007;110:230–40. 73% Subjects(%) Aches Subjects(%) Decreased libido Subjects(%) Depression 80 60 40 20 0 Subjects(%) Vaginal dryness Subjects(%) Hot flushes Subjects(%) Poor sleep Menopausal stage Menopausal stage Mild Moderate or severe 80 60 40 20 0 80 60 40 20 0 80 60 40 20 0 80 60 40 20 0 80 60 40 20 0
  • 8. Figure modified with permission from Obermeyer CM, Menopause Across Cultures: A Review of the Evidence, Menopause, 7, 3:184-92. Comparative Frequencies of Hot Flushes in Different Parts of the World • A review of cross-cultural evidence on vasomotor symptoms from available studies
  • 9. HRT Remains the Most Effective Therapy for Vasomotor Symptoms 2006 • No significant efficacy of botanicals in reducing vasomotor symptoms Newton KM et al. Ann Intern Med 2006;145:869–79. Reprinted from Annals of Internal Medicine, 145, Newton et al, Treatment of Vasomotor Symptoms of Menopause with Black Cohosh, Multibotanicals, Soy, Hormone Therapy, or Placebo, 869-879, Copyright (2006), with permission from American College of Physicians. Baseline 3 months 6 months 12 months 0 1 2 3 4 5 6 7 8 Vasomotorsymptomsperday Black Cohosh Multibotanical Multibotanical + soy HRT: CEE +/- MPA Placebo
  • 10. Outline • Menopausal transition • HRT modalities • Risks & Benefits • Emerging concept
  • 11. Uterus Sequential therapy without tablet break Regular bleeding at end of cycle How is HRT Given? Continuous Sequential HRT Estrogen Progestogen Day 14 De Villiers TJ et al. Climacteric 2013;16:316–337. . Continuous Estrogen Estrogen No tablet break No bleeding as no uterus Uterus Continuous Combined HRT Estrogen Progestogen Day 14 Combined therapy without tablet break No bleeding at end of cycle
  • 12. Estrogens Used in HRT 2007 Equivalent dose for bone endpoints* Estrogen Ultra Low Low Standard High Conjugated equine estrogens (mg) 0.151 0.3 0.625 1.25 Micronized 17β-estradiol (mg) 0.52 1 2 4 Estradiol valerate (mg) 1 2 Transdermal 17β-estradiol (μg) 143 25 50 100 *Estrogenic effects may vary for other endpoints Table reproduced from Maturitas, 40, Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. 195–201, Copyright (2001), with permission from Elsevier. 1. Lindsay R et al. Obstet Gynecol 1984;63:759–63; 2. Panay N et al. Climacteric 2007;10:120–31; The Estrogen Dose Counts
  • 13. Estradiol: Benefits on Vasomotor Symptoms • Dose–response effect for reducing moderate-to-severe hot flushes (n=333) Figure reproduced with permission from Notelovitz M, Lenihan JP, Mcdermott M, Kerber IJ, Nanavati N, Arce JC. Initial 17β-Estradiol Dose for Treating Vasomotor Symptoms. Obstet Gynecol 2000;95:726–31. *p<0.05, ***p<0.001 vs. placebo * * Meannumberofmoderate-to- severehotflushesperweek Weeks 0 10 20 30 40 50 60 70 80 0 1 2 3 4 5 6 7 8 9 10 11 12 Placebo 0.25 mg Estradiol 0.5 mg Estradiol 1 mg Estradiol 2 mg Estradiol *** *** *** * * *
  • 14. Role of Progestogens in HRT • Estrogen provides the benefits of HRT on menopausal symptoms • For women who have not had a hysterectomy, the addition of a progestogen to HRT is necessary to protect the endometrium from the stimulatory effects of unopposed estrogen Writing Group for the PEPI Trial. JAMA 1996;275:370–5. PEPI Trial: multicenter RCT : Results of Endometrial Biopsy Conclusion: Adding a progestogen is needed to safeguard the endometrium Placebo CEE alone CEE+MPA sequential CEE+MPA continuous N 119 119 118 120 Normal 98% 38% 95% 99% Simple hyperplasia 1% 28% 3% 1% Complex hyperplasia 1% 23% 2% 0% Atypia 0% 12% 0% 0% Adenocarcinoma 1% 0% 0% 0%
  • 15. Progestogens: Receptor Binding Activity Progestogen Progestogenic Estrogenic Androgenic Anti- androgenic Glucocorticoid Anti-mineralo- corticoid Progesterone + – – ± + + Dydrogesterone + – – ± – ± Drospirenone + – – + – + MPA + – ± – + – Norethisterone + + + – – – Table reproduced from Maturitas, 46 (S1), Schindler AE, Campagnoli C, Druckman R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JHH. Classification and pharmacology of progestins. 7–16. Copyright (2003), The Progestogen Counts • All progestogens have a protective effect on the endometrium • However, not all progestogens have the same receptor binding effect + Effective; ± Weakly effective; – Not effective
  • 16. 2013 IMS Recommendations on Menopausal Hormone Therapy – General Principles for Use • HRT remains the most effective therapy for vasomotor symptoms • Use lowest effective dose of estrogen • More favorable if treatment is started earlier in menopause De Villiers TJ et al. Climacteric 2013;16:316–337. .
  • 17. Outline • Menopausal transition • HRT modalities • Risks & Benefits • Emerging concept
  • 18. HRT Risks and Benefits Benefits Relief of Menopause Symptoms Risks Breast Cancer
  • 19. Odds ratio (fixed) 95% CI 1.00 [0.68, 1.46] 1.02 [0.06, 16.44] 0.92 [0.41, 2.07] 0.98 [0.78, 1.22] 0.50 [0.04, 5.54] 0.32 [0.01, 8.24] 0.97 [0.06, 15.82] 2.64 [0.10, 66.41] 0.33 [0.01, 8.21] 0.97 [0.54, 1.72] 1.79 [0.42, 7.67] 1.26 [0.96, 1.64] 0.97 [0.78, 1.21] Total 1.03 [0.91, 1.16] HRT Reduced the Risk of CHD events in Younger Postmenopausal Women (2006)In a meta-analysis of data from 23 studies (n=39,049) • HRT reduced CHD events by 32% in younger* women • In older women**, there was no reduction in CHD with HRT (OR 1.03; CI 0.91 to 1.16) *<10 years post-menopause or <60 years; **≥10 years post-menopause or ≥60 years CHD, coronary heart disease; OR, odds ratio Odds ratio (fixed) 95% CI 3.03 [0.12, 75.28] 0.16 [0.01, 4.12] 3.03 [0.12, 75.06] 1.00 [0.06, 16.10] 0.33 [0.01, 3.19] 1.25 [0.06, 26.10] 0.33 [0.01, 8.12] 0.31 [0.01, 8.29] 0.05 [0.00, 1.16] 0.12 [0.00, 2.93] 0.87 [0.53, 1.41] 0.56 [0.30, 1.03] Total 0.68 [0.48, 0.96] 0.001 Favors HT Favors control Favors HT 0.01 0.1 1 10 100 Favors control Older women** 1000.01 0.1 1 10 Younger women* Figure reproduced with kind permission from Springer Science+Business Media: J Gen Intern Med, Coronary Heart Disease Events Associated with Hormone Therapy in Younger and Older Women, 21, 2006, 363-66, Salpeter SR, Walsh JME, Greyber E, Salpeter EE, Figures 1 & 2.
  • 20. HRT and the Risk of Ischemic Stroke (WHI) Risk of Ischemic Stroke • The use of estrogen-only and estrogen-progestogen therapy is associated with an up to 1.5-fold increased relative risk of ischemic stroke. The risk of hemorrhagic stroke is not increased during use of HRT. This relative risk is not dependent on age or on duration of use, but as the baseline risk is strongly age-dependent, the overall risk of stroke in women who use HRT will increase with age US WHI studies combined - additional risk of ischemic stroke1 over 5 years’ use Age range (years) Incidence per 1,000 women in placebo arm over 5 years Risk ratio (95% CI) Additional cases per 1,000 HRT users over 5 years (95% CI) 50–59 8 1.3 (1.1–1.6) 3 (1–5) 1No differentiation was made between ischemic and hemorrhagic stroke
  • 21. Risk of Stroke Associated with Route of Administration (2010) • Case-control study from the UK General Practice Research Database Renoux C et al. BMJ 2010;340:c2519. • Low-dose transdermal HRT did not appear to increase stroke risk (1.15– 3.11) (0.62– 1.05) (1.12– 1.40) (1.16– 1.90) AdjustedRRvs.never-use ofHRT(95%CI)
  • 22. Risk of Thromboembolism Associated with Different Progestogens (2007) ESTHER case-control study 271 consecutive VTE cases (mean age: 61.6 years) and 610 controls (mean age: 61.5 years) Canonico M. Circulation 2007;115:840–5. AdjustedORs(95%CI)for VTEwithoralandtransdermal estrogenvs.non-users (e.g. Dydrogesterone)  Micronized progesterone and dydroprogesterone appear to have an acceptable thrombotic risk profile 4.2 (1.5–11.6) 0.7 (0.3–1.9) 0.9 (0.4–2.3) 3.9 (1.5–10.0) (e.g. Nomegestrol acetate)
  • 23. Breast Cancer with HRT: Risk Perception vs. Reality Figure reproduced with permission from http://www.keepstudy.org/why_keeps/keeps_causeDeath.pdf. Accessed 1 November 2012 PERCEPTION Leading causes of death perceived by women REALITY Actual causes of death among US women Old age (1%) Heart disease (18%) Other cancer (13%) Breast cancer (39%) Lung cancer (2%) Ovarian cancer (9%) Stress (2%) Smoking (1%) Other/don’t know (16%) Heart disease (45%) Other (25%) Lung cancer (5%) Ovarian cancer (<2%) COPD (4%) Pneumonia (4%) Other cancer (11%) Breast cancer (4%)
  • 24. Growth 1 cm 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Years 2.5 cm1 mm Pre-mammographic Mammographic Window Clinically detected Breast Tumor Chronological Development of Breast Cancer 2011 Fritz MA and Speroff L. Clinical Gynecologic Endocrinology and Infertility (8th edn) Wolters Kluwer 2011; pp. 667–8.
  • 25. Is HRT Associated with Increased Breast Cancer Risk? Evidence from WHI 1. Rossouw JE et al. JAMA 2002;288:321–33; 2. Langer R et al. Climacteric 2012;15:206–12; 3. Stefanik M et al. JAMA 2006;295:1647–57; 4. Santen R et al. J Clin Endocrinol Metab 2010;95(Suppl 1):s1–66; 5. Gompel A et al. Climacteric 2012;15:241–9. WHI evidence WHI RR for breast cancer: 1.26 (95% CI 1.00–1.59) for current use of HRT (CEE + MPA)1 Relative risk of 1.26 with combined HRT translates to an excess (attributable) risk of 4 per 1000 women taking HRT for 5 years4 Excess risk of breast cancer from HRT increases with increase in underlying risk5 Determination of risk should underlie decision to use HRT • No increased risk was identified for women who had had hysterectomy receiving CEE alone 2012
  • 26. HRT and Breast Cancer Risk - WHI US WHI studies – additional risk of breast cancer after 5 years’ use Age range (years) Incidence per 1,000 women in placebo arm over 5 years Risk ratio (95% CI) Additional cases per 1,000 HRT users over 5 years (95% CI) CEE estrogen-only 50–79 21 0.8 (0.7–1.0) -4 (-6–0)1 CEE + MPA 50–79 14 1.2 (1.0–1.5) +4 (0–9) When the analysis was restricted to women who had not used HRT prior to the study there was no increased risk apparent during the first 5 years of treatment: after 5 years the risk was higher than non-users 1 WHI study in women with no uterus, which did not show an increase in risk of breast cancer Netherlands Summary of Product Characteristics (SmPC) , estradiol/dydrogesterone 2/10, 1/10, 1/5, 0.5/2.5 issued 13 April 2012.
  • 27. HRT and Breast Cancer Risk – Million Women Study Million Women Study – Estimated additional risk of breast cancer after 5 years’ use Age range (years) Additional cases per 1,000 never users of HRT over a 5 year period1 Risk ratio (95% CI) # Additional cases per 1,000 HRT users over 5 years (95% CI) Estrogen only HRT 50–65 9–12 1.2 1–2 (0–3) Combined estrogen-progestogen 50–65 9–12 1.7 6 (5–7) # Overall risk ratio. The risk ratio is not constant but will increase with increasing duration of use Note: Since the background incidence of breast cancer differs by EU country, the number of additional cases of breast cancer will also change proportionately 1Taken from baseline incidence rates in developed countries Netherlands Summary of Product Characteristics (SmPC) , estradiol/dydrogesterone 2/10, 1/10, 1/5, 0.5/2.5 issued 13 April 2012.
  • 28. Choice of Progestogen and Breast Cancer Risk: E3N French Cohort Study 2008 Fournier A et al. Breast Cancer Res Treat 2008;107:103–11; Fournier A et al. J Clin Oncol. 2008 ;26:1260–1268. Risk of all breast cancer Risk elevation may not be uniform for all progestogens N = 80,377 women, for an average treatment duration of 8.1 years Overall 77.7% were ductal breast cancers vs. 22.3% lobular breast cancers Estrogen/other progestogens (0.83– 1.22) (0.94– 1.43) (1.50– 1.91) 1.16 1.00 Estrogen/ progesterone Baseline risk without HRT Estrogen/ dydrogesterone 1.69 0 0.2 0.4 0.8 1.2 1.6 1.0 2.2 2.0 1.8 1.4 0.6 Relativerisk(95%CI) ≥5 years (0.8– 1.5) (0.8– 2.7) (1.2– 3.8) 1.5 1.1 ≥5 years<5 years <5 years 2.1 0 0.2 0.4 0.8 1.2 1.6 1.0 2.2 2.0 1.8 1.4 0.6 Ductal carcinoma Lobular carcinoma 1.1 (0.8– 1.17) Risk of breast cancer subtypes with E/D Significantly different from the risk without HRT Not statistically significantly different from risk without HRT
  • 29. Choice of Progestogen and Breast Cancer Risk: Finnish Cohort Study 2009 Lyytinen H et al. Obst Gyn 2009;113:65–73. Estradiol/ MPA Estradiol/other progestogens Standardincidenceratio(95%CI) 0 0.2 0.4 0.8 1.2 1.6 1.0 2.2 2.0 1.8 1.4 0.6 2.072.03 1.64 1.13 Estradiol/ dydrogesterone Estradiol/ NETA (0.49– 2.22) (1.49– 1.79) (1.88– 2.18) (1.76– 2.04) Baseline risk without HRT Risk elevation may not be uniform for all progestogensRisk elevation may not be uniform for all progestogens N = 50,210 women >50 years of age, treatment duration 5 years
  • 30. Statements from International Societies 2013 International Menopause Society Statement on Breast Cancer1 • Women should be reassured that the possible increased risks of breast cancer associated with HRT are small • an incidence of <1.0 per 1000 women per year of use • Less than the increased risks associated with common lifestyle factors such as reduced physical activity, obesity and alcohol consumption • Micronized progesterone or dydrogesterone used with estradiol may be associated with a better risk profile for breast cancer than synthetic progestogens 1. De Villiers TJ et al. Climacteric 2013;16:316–337. 2. Santen R et al. J Clin Endocrinol Metab 2010;95(Suppl1):S1–S66. USA Endocrine Society Scientific Statement on Breast Cancer2 • Emerging data from 2 independent studies suggest that progesterone (and perhaps dydrogesterone) in combination with estrogen does not increase breast cancer risk if given for 5 years or less
  • 31. Outline • Menopausal transition • HRT modalities • Risks & Benefits • Emerging concept
  • 32. Sequential Estradiol/Dydrogesterone: Endometrial Safety and Bleeding • In a comparison of 1/5 or 1/10 vs. 2/10 or 2/20 (n=579)1 – Endometrial safety was recorded across groups • No cases of hyperplasia or malignancy with 1/10 and 2/10 • 1 polyp occurred with 1/10 – Cyclic bleeding patterns were seen • Percentage of women with cyclic bleeding was 79% with 1/10 and 91% with 2/10 • E 1 mg associated with less cyclic and intermittent bleeding vs. E 2 mg • Higher doses of D associated with higher incidence of bleeds and later day of onset • In a comparison of 2/5, 2/10, 2/15 or 2/20 (n=371):2 – Endometrial safety was recorded across groups • No cases of hyperplasia or malignancy with 1/10 and 2/10 – Cyclic bleeding patterns found at all doses (83%, 90%, 87%, 93%, respectively) • Percentage of women with cyclic bleeding was 90% with 2/10 1. Ferenczy A et al. Climacteric 2002;5:26–35; 2. Burch DJ et al. Brit J Obst Gynaecol 1995;102:243–8.
  • 33. Continuous Estradiol/Dydrogesterone: Endometrial Safety and Bleeding Patterns 2010 • In an open, multicenter study of 1/5 for 1 year (n=290):1 • 1 case of simple hyperplasia without atypia (treatment failure rate of 0.4%) • Women without bleeding increased from 71% (cycle 1) to ~80% by end of the study • ~50% of bleeding episodes were spotting • 41% women were amenorrheic throughout the study • 7 women withdrew prematurely due to uterine bleeding • In an open, multicenter study of ultra-low-dose 0.5/2.5 over 1 year (n=446):2 • 1 case of simple hyperplasia (incidence: 0.27%) • 68% experienced amenorrhea (88% during months 10–12) • 14% had 1 or 2 bleeding/spotting episodes • Spotting alone was the most prevalent bleeding intensity; heavy bleeding was rare 1. Quereux C et al. Maturitas 2006;53:299–305; 2. Bergeron C et al. Maturitas 2010;66:201–5.
  • 34. The emerging concepts in HRT • Timing (window of opportunity) • Early start • Maintenance of estrogenic benefits • Patient selection • Avoiding generalized prescribing • Personalization • Tailoring dose to patient • Continuation and tapering the dose with age
  • 35. Conclusion Used by the right woman, at the right dose, HRT can: • Relieve vasomotor and other menopausal symptoms • Provide protection against bone loss (second line) • Provide acceptable bleeding patterns